Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aptose Biosciences Inc (APS.TO)

Aptose Biosciences Inc (APS.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 5,130
  • Shares Outstanding, K 2,552
  • Annual Sales, $ 0 K
  • Annual Income, $ -25,430 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta -0.41
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.74 +15.52%
on 12/17/25
2.37 -15.19%
on 12/03/25
-0.28 (-12.23%)
since 11/24/25
3-Month
1.50 +34.00%
on 10/03/25
2.44 -17.62%
on 11/19/25
+0.38 (+23.31%)
since 09/23/25
52-Week
1.02 +97.06%
on 06/18/25
12.60 -84.05%
on 02/20/25
-8.94 (-81.64%)
since 12/24/24

Most Recent Stories

More News
Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SEC

SAN DIEGO and TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“ Aptose ” or the “ Company ”) (TSX: APS; OTC: APTOF) announced today that it will be rescheduling its upcoming...

APTOF : 1.4500 (-3.97%)
APS.TO : 2.01 (-4.29%)
Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations

TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed AML patients with diverse mutations Safety continues to be a notable hallmark...

APTOF : 1.4500 (-3.97%)
APS.TO : 2.01 (-4.29%)
Upcoming Meeting Dates - December 1, 2025

Toronto, Ontario--(Newsfile Corp. - December 1, 2025) - The following is a list of Upcoming Meeting Dates for Reporting Issuers in Canada. The data is supplied by Issuing Companies through the service...

EVM.CN : 0.0150 (unch)
PINK.VN : 0.435 (+2.35%)
UE.CN : 0.0750 (unch)
FIN.VN : 0.095 (unch)
W.VN : 0.450 (unch)
MLKM.CN : 0.0300 (unch)
ZONE.VN : 0.015 (unch)
NVPC.CN : 0.0400 (unch)
WBGD.CN : 0.0950 (unch)
HOLD.NE : 0.0950 (+18.75%)
ALY.VN : 0.020 (unch)
APS.TO : 2.01 (-4.29%)
Aptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical

SAN DIEGO and TORONTO, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF) and Hanmi Pharmaceutical Co. Ltd. (“Hanmi”) today announced...

APTOF : 1.4500 (-3.97%)
APS.TO : 2.01 (-4.29%)
Aptose Biosciences: Q3 Earnings Snapshot

Aptose Biosciences: Q3 Earnings Snapshot

APS.TO : 2.01 (-4.29%)
Aptose Reports Third Quarter 2025 Results

Tuspetinib Continues to Demonstrate Excellent Safety and Complete Responses in the TUSCANY Clinical Trial of Tuspetinib in AML Triple Drug Frontline Therapy at Increased Dose Levels Patients are Now...

APTOF : 1.4500 (-3.97%)
APS.TO : 2.01 (-4.29%)
Aptose Tuspetinib Clinical Data from Ongoing TUSCANY Trial in Newly Diagnosed AML Selected for Presentation at the 2025 ASH Annual Meeting

SAN DIEGO and TORONTO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS), a clinical-stage precision oncology company developing a tuspetinib (TUS)...

APTOF : 1.4500 (-3.97%)
APS.TO : 2.01 (-4.29%)
Stocks in play: Aptose Biosciences Inc.

Today announced that data from the ongoing TUSCANY trial of tuspetinib in combination with venetoclax ...

APS.TO : 2.01 (-4.29%)
Aptose’s Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML

Addition of TUS to VEN+AZA achieves CR/CRh responses in all (6/6, 100%) patients treated at the higher dose levels of 80 mg and 120 mg TUS, exceeding the 66% rate expected from VEN+AZA alone CR/CRh...

APTOF : 1.4500 (-3.97%)
APS.TO : 2.01 (-4.29%)
Aptose and Hanmi Pharmaceutical Extend Loan Agreement to Continue Development of Tuspetinib in Triplet Therapy for AML

SAN DIEGO and TORONTO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib...

APTOF : 1.4500 (-3.97%)
APS.TO : 2.01 (-4.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance...

See More

Key Turning Points

3rd Resistance Point 2.16
2nd Resistance Point 2.13
1st Resistance Point 2.07
Last Price 2.01
1st Support Level 1.98
2nd Support Level 1.95
3rd Support Level 1.89

See More

52-Week High 12.60
Fibonacci 61.8% 8.18
Fibonacci 50% 6.81
Fibonacci 38.2% 5.44
Last Price 2.01
52-Week Low 1.02

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar